Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Friday, April 7, 2017

Angiotensin II Receptor Blockers May Reduce Age-Related Cognitive Decline

Any followup at all to see if this might help stroke cognitive decline? Or will nothing occur because we have NO STROKE LEADERSHIP?
By Thomas S. May
FLORENCE, Italy -- April 5, 2017 -- Individuals treated with angiotensin II receptor blockers (ARBs), including losartan, valsartan, and candesartan, experience a decreased risk for age-related cognitive decline and dementia, according to results of a cross-sectional analysis presented at the 25th European Congress of Psychiatry (EPA).
Lead author Dominik Wincewicz, MD, Medical University of Bialystok, Bialystok, Poland and colleagues observed a significant decrease in the risk for cognitive decline in subjects who received ARB treatment over the course of approximately 9 years of follow up (odds ratio [OR] = 0.445, 95% confidence interval [CI] = 0.22 to 0.90, P = .024). The risk of dementia also was decreased significantly in participants treated with ARBs (hazard ratio [HR] = 0.621, 95% CI = 0.40 to 0.98, P = .038), added Dr. Wincewicz, speaking here on April 2.
He and his fellow investigators analysed data from the population-based, longitudinal Kuopio Ischemic Heart Disease (KIHD) Risk Factor Study, an extensive epidemiologic research project launched in the 1980s, which initially involved nearly 3,000 middle-aged men from the Kuopio region in Eastern Finland. A decade later, over 1,000 women of the same age were recruited to the study. A major part of the original cohorts have been re-examined 4, 11, and 20 years after the baseline.
The researchers included a total of 1,774 subjects (920 females; baseline age range: 42 to 61 years). They utilised a cut-off score of ≥ 2 point decrease in the Mini-Mental-State Examination over a 9-year follow-up period to detect age-related cognitive decline, and a hospital discharge diagnosis of dementia as the outcome variable for dementia.
Using logistic regression, the investigators determined cross-sectional relationships, and conducted prospective analyses with the Cox proportional hazards model. The team adjusted analyses for all relevant background variables.
ARBs modulate the brain renin-angiotensin system (RAS), and have been shown to improve cognitive functioning in animal models of neuropsychiatric disorders. The brain RAS also has been considered as a new target for the treatment of Alzheimer’s Disease.
[Preserved Cognition and Reduced Age Related Cognitive Decline During Treatment with Angiotensin II Receptor Blockers: a 20-year Follow-up Study. Abstract ED773]

No comments:

Post a Comment